The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

IMW 2019 | Reducing CAR-T toxicity

Name: Reducing CAR-T toxicity
Uploaded: 2019-09-15T00:00:00.000Z
Duration: 3 min 9 s
Description: Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA describes how CAR-T cells may be used to reduce the toxic effects of therapy and the promise of new antibody-drug conjugates. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Yu-Tzu Tai • 15 Sep 2019

IMW 2019

Multiple Myeloma CAR-T

Dr. Yu-Tzu Tai, PhD of the Dana-Farber Cancer Institute, Boston, MA describes how CAR-T cells may be used to reduce the toxic effects of therapy and the promise of new antibody-drug conjugates. Recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.